Sodium sulfate anhydrous
As of the edition of 20 October 2026, Sodium sulfate anhydrous is a small molecule: marketed, first approved in 1970 (CH).
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2021
- Kind
- Small molecule
- Brand name
- Golytely
- First approved
- 17 November 1970 (CH)
- Approvals on record
- 20 in 3 regions
- Holder of the most recent approval
- Azurity Pharmaceuticals; 9 holders in all
- Registered trials
- 28, 0 stopped early
- Disease areas
- Digestive system; Cancer; Mental health; Hormones; Injuries; Mouth and teeth
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 8 | 3 | 1 | 0 |
| Phase 1 | 2 | 2 | 0 | 0 |
| Phase 2 | 5 | 3 | 1 | 0 |
| Phase 3 | 3 | 2 | 1 | 0 |
| Phase 4 | 10 | 7 | 2 | 0 |
| All trials | 28 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Nihon Pharmaceutical | Applicant | 2021 to now |